Engineering scFv immunotherapies: From CAR T cells to bispecific antibodies
Authors:
- 1 October 2025
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 166, 115597
Abstract
No abstract availableKeywords
Funding Information
- King Khalid University (RGP-2/205/45)
This publication has 82 references indexed in Scilit:
- Single-domain antibodies as therapeutics for solid tumor treatmentActa Pharmaceutica Sinica B, 2024
- Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal AntibodiesBioDrugs, 2024
- F77 antigen is a promising target for adoptive T cell therapy of prostate cancerBiochemical and Biophysical Research Communications, 2023
- CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancerJournal of Cancer Research and Clinical Oncology, 2022
- Anthrax Protective Antigen Retargeted with Single‐Chain Variable Fragments Delivers Enzymes to Pancreatic Cancer CellsChemBioChem, 2020
- Construction, expression and functional analysis of anti-B7-H4-scFv-CH3 recombinant antibodyJournal of Biosciences, 2018
- Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expressionCancer Immunology, Immunotherapy, 2018
- Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopesBreast Cancer Research and Treatment, 2018
- Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13–ETA′ and the bispecific scFv [13xds16]Journal of Cancer Research and Clinical Oncology, 2017
- Preventive DNA vaccination against CEA-expressing tumors with anti-idiotypic scFv6.C4 DNA in CEA-expressing transgenic miceCancer Immunology, Immunotherapy, 2016